MedTrace Logo

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-02-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).

Conditions

  • Raised Intraocular Pressure

Interventions

DRUG

AZD4017

tablet, oral, one tablet once daily, 28 days

DRUG

Placebo

matching placebo tablet, oral, one tablet once daily, 28 days

DRUG

AZD4017

tablet, oral 2 tablets twice daily, 28 days

DRUG

Placebo

matching placebo tablets, oral, 2 tablets twice daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Heather Bryson, PhD · AstraZeneca R&D

  • Tony Ho, MD · AstraZeneca R&D

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173471 on ClinicalTrials.gov